Antibiotic-Resistant Cytomegalovirus Infection Following Oral Valganciclovir Prophylaxis in Lung Transplant Recipients

CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 546A
Author(s):  
Linda J. Stuckey ◽  
Anish Wadhwa ◽  
Daniel Kaul ◽  
Kristy Bauman ◽  
Vibha N. Lama ◽  
...  
Keyword(s):  
Cytomegalovirus Infection ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Antibiotic Resistant ◽  
Oral Valganciclovir ◽  
Lung Transplant Recipients

Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature

2017 ◽  
Vol 32 (2) ◽  
pp. e13176 ◽  
Author(s):  
Jose Tiago Silva ◽  
Virginia Pérez-González ◽  
Francisco Lopez-Medrano ◽  
Rodrigo Alonso-Moralejo ◽  
Mario Fernández-Ruiz ◽  
...  
Keyword(s):  
Cytomegalovirus Infection ◽  
Lung Transplant ◽  
Case Series ◽  
Secondary Prophylaxis ◽  
Transplant Recipients ◽  
Review Of The Literature ◽  
Lung Transplant Recipients

Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients

2018 ◽  
Vol 20 (4) ◽  
pp. e12893 ◽  
Author(s):  
Nikta Jaamei ◽  
Angela Koutsokera ◽  
Jérôme Pasquier ◽  
Matteo Mombelli ◽  
Pascal Meylan ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Cytomegalovirus Infection ◽  
Lung Transplant ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

scholarly journals Low-Dose Valganciclovir for CMV Prophylaxis after Lung Transplantation

2013 ◽  
Vol 2013 ◽  
pp. 1-6
Author(s):  
Hargobind S. Khurana ◽  
Alison Kole ◽  
Jeremy Falk ◽  
Sara Ghandehari ◽  
Guy Soohoo ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Lung Transplant ◽  
Low Dose ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Female Ratio ◽  
Oral Valganciclovir ◽  
Lung Transplant Recipients ◽  
Cmv Disease ◽  
Cmv Prophylaxis

Purpose. Cytomegalovirus (CMV) remains an important pathogen following solid organ transplantation (SOT). Universal prophylaxis for CMV is adopted by most centers after lung transplantation. Various combinations studied for CMV prophylaxis include intravenous and oral ganciclovirs, oral valganciclovir, and CMV immunoglobulins. We present our experience with a low-dose of oral valganciclovir for CMV prophylaxis following lung transplantation. Methods and Materials. Our center started using 450 mg of daily oral valganciclovir for CMV prophylaxis in lung transplant recipients in Jan, 2001. A retrospective chart analysis of patients who underwent lung transplantation from January 2001 to December 2006 was done. Of 46 patients, 4 were excluded as they died within 30 days of transplant from postop complications. The mean age at transplant was 64 years, mostly single lung transplants (36/6) with a male-to-female ratio of 25/17. COPD was the most common reason for transplant (65%), and the serological CMV status of donors (D) and recipients (R) was as follows: D+/R+ 28, D+/R− 5, D−/R+ 5, and D−/R− 4. Valganciclovir was given for a total of 6 months posttransplant except for D−/R+ patients who received it for 12 months. Results. Five patients (12%) developed CMV disease with an average followup of 26 months. Only 2 (4.7%) developed CMV disease within six months of completing valganciclovir prophylaxis. This incidence is not significantly different from the best-reported results of CMV prophylaxis in lung transplant recipients. The remaining 3 patients developed the disease later in their course, one as late as 32 months posttransplant. The main side effects noted include leucopenia, neutropenia, and GI disturbances. However, the number of patients who had to temporarily stop or discontinue the medication (9.5%) was significantly lower than that reported in previous studies. Conclusions. Our experience suggests that low-dose valganciclovir is an effective method of prophylaxis for CMV disease in high-risk patients. It is a simple regimen that seems to have a better side effect profile and to improve patient compliance.

Sign in / Sign up

Export Citation Format

Share Document